Optimum Perspectives

It’s time to talk about mushrooms! Or rather the deadly toxin amanitin found in the death cap mushroom, which Heidelberg Pharma is using as a cancer drug with the help of a tumour-targeting antibody, find out more in this episode featuring Heidelberg Pharma's CEO, Andreas Pahl.

Check out Optimum’s latest podcast episode profiling our client Resolution Therapeutics. Lara Campana, VP of Research Operations outlines the company’s technology based around pro-regenerative macrophages and its potential to treat liver disease.

Dr Ruth McKernan CBE is the richly deserved winner of the 2024 Mediscience Award for ‘Most Significant Contribution to the Mediscience Sector’. In this episode Optimum’s Eva Haas discusses the highlights of Ruth’s incredible career, the skills needed for success as a company founder and the heartening advancements in treating neurodegenerative diseases such as Alzheimer's in recent years.

Listen to expert discussion on the role of AI in drug development, featuring Tushar Pandey, CEO and Co-founder of SimBioSys, and Jeremy Skillington, CEO of Poolbeg Pharma.

Southampton-based Curve Therapeutics recently raised a hefty £40m in a Series A financing round. In this in-depth podcast, CEO Simon Kerry describes how investors fell in love with Curve’s “Microcycle” based discovery platform, which gives the company “the ability to potentially identify drugs against very difficult, challenging targets”.He explains how Curve’s platform enables them to spot drugs with a higher chance of working in real-world conditions. He also outlines the firm’s lead programme – which aims to block two cancer targets called Hypoxia Inducible Factors, or “HIFs”, which enable solid tumours to survive in low-oxygen conditions.Speaking to Optimum’s Stephen Adams, Simon ponders the role of luck in securing investment, both “the kind you deserve because you turn over a lot of stones”, and the more fortuitous variety.

Listen to the latest insights from Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International, on how to succeed in the new wave of biotech IPOs in the Optimum Perspectives podcast.

Check out Optimum’s latest Optimum Perspectives Podcast episode featuring the stars of the 20th Anglonordic Life Science Conference in London. Hear industry leaders give their thoughts on trends within the life science industry and the optimistic mood of the markets in 2024!

Diverse recruitment for clinical trials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum’s Richard Staines as he discuses this thorny issue with Ariceum Therapeutic’s CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Non-Executive Director & Thought Leader Annalisa Jenkins.

Following recent encouraging interim clinical results, hear Øystein Rekdal, CEO of Lytix Biopharma, discuss with Optimum's Nick Bastin how the company's lead candidate LTX-315 has a unique approach to killing cancer.